-
ASCO Expert Commentary | Professors Xuesong Li, Qi Tang, and Xiaoying Li: Addressing the Unique Challenges of UTUC in China—Disitamab Vedotin Paves the Way for a New Era in Adjuvant Therapy
Oncology Frontier – UroStream UTUC has a different pathogenesis compared to bladder cancer, and Chinese UTUC cases differ significantly from those in Western populations. Therefore, Western treatment paradigms cannot be…
-
Professor Jiwei Huang: The “Renji Experience” in Neoadjuvant Therapy for UTUC | CUDA 2025
The 2025 Annual Meeting of the Chinese Urological Association (CUDA), held from June 12 to 15 in the romantic city of Zhuhai, brought together leading experts under the theme “Healthy China, Urology First.” At the conference, Professor Jiwei Huang from Renji Hospital, Shanghai Jiao Tong University School of Medicine, delivered a compelling presentation on neoadjuvant…
-
Voices from China at ASCO | Prof. Yiding Chen: Biomarker Analysis from the DANCER Study Opens a New Chapter in Precision Therapy for Breast Cancer
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting took place from May 30 to June 3 in Chicago. At this global event, Professor Yiding Chen from the Second Affiliated Hospital, Zhejiang University School of Medicine, presented results from the biomarker analysis of the DANCER study. Focusing on operable HER2-negative Luminal B breast cancer,…
-
ASCO Global Perspective | Prof. Giuseppe Curigliano Shares New Insights into HR+/HER2− Breast Cancer Treatment Based on PRO Data from the EMBER-3 Trial
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, ESMO President-Elect Professor Giuseppe Curigliano of the European Institute of Oncology (IEO), Milan, Italy, presented findings from the patient-reported outcomes (PRO) analysis of the Phase III EMBER-3 trial. The data revealed changes in overall health status, quality of life, and physical function scores in…
-
Voices from China at ASCO | Professor Junjie Li: Promising Data from HER2 Bispecific ADC TQB2102 Signals New Hope for Neoadjuvant Therapy in HER2-Positive Breast Cancer
Antibody–drug conjugates (ADCs) targeting HER2 have already transformed the treatment landscape in advanced breast cancer and are now making their way into early-stage settings. At the 2025 ASCO Annual Meeting, Professor Junjie Li from Fudan University Shanghai Cancer Center presented results from a phase II clinical study investigating a novel HER2 bispecific ADC, TQB2102, in…
-
Voices from China at ASCO | Professor Ting Li: Innovative Triple Combination with Adebrelimab, Bevacizumab,cisplatin/carboplatin Brings New Hope to TNBC Patients with Brain Metastases
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting was held in Chicago from May 30 to June 3. At the conference, Professor Ting Li of Fudan University Shanghai Cancer Center delivered a Rapid Oral Abstract presentation on behalf of her team, showcasing a phase II clinical study (Abstract #1018) titled “A phase II…
-
Voices from China at ASCO | Professor Jieqiong Liu：Exploring a new path for the treatment of metastatic breast cancer——analysis of the microenvironment of combination therapy
A dynamic understanding of the tumor microenvironment (TME) is essential for uncovering the mechanisms behind treatment response and disease progression. At the 2025 ASCO Annual Meeting, Professor Jieqiong Liu from Sun Yat-sen Memorial Hospital, Sun Yat-sen University, presented an innovative translational study (Abstract #1022) exploring the efficacy and safety of a novel combination therapy in…
-
Dr. Qu Fajun Showcases Single-Port Robotic Hood Technique for Scarless Prostate Surgery
At the forefront of surgical innovation, Dr. Qu Fajun (Changzheng Hospital) presented a refined interpretation of the Hood technique using a cutting-edge single-port robotic platform. Aiming to elevate prostate cancer…
Connecting Medical Expertise through Media